Chlamydia trachomatis is an obligate, intracellular pathogen responsible for the most common bacterial sexually transmitted disease worldwide, causing acute and chronic infections. The acute infection is susceptible to antibiotics, while the chronic one needs prolonged therapies, thus increasing the risk of developing antibiotic resistance. Novel alternative therapies are needed.
Introduction
Chlamydia trachomatis, an obligate intracellular pathogen, is the leading cause of bacterial sexually transmitted infections in the world with an estimated over 131 million new cases per year (Newman et al. 2015) . C. trachomatis genital infection manifests in women as cervicitis, salpingitis and endometritis, and can progress leading to severe sequelae, such as pelvic inflammatory disease, ectopic pregnancy and obstructive infertility (Shaw et al. 2011 ). Importantly, a major concern with chlamydial genital infections is that approximately 80% of women are asymptomatic, thus resulting in a reservoir for onwards transmission in the population (Shaw et al. 2011) .
C. trachomatis is characterized by a unique biphasic developmental cycle alternating between the extracellular infectious bodies (Elementary Bodies, EBs), metabolically inactive, and the intracellular non-infectious bodies (Reticulate Bodies, RBs), metabolically active. The EBs adhesion and entry into mucosal epithelial cells initiate a signal transduction cascade of the host cell, leading to the recruitment and reorganization of the actin cytoskeleton at the site of attachment.
Following the fusion of EB-containing endosomes, EBs develop into larger, metabolically active but non-infectious RBs. Using ATP and nutrients from the host cell, RBs grow and divide by binary fission within a membrane-bound vacuole, termed inclusion. Subsequently, the RBs asynchronously transform into EBs, which are released, after approximately 48 hours, from the host cell by lysis (Wyrick 2010; Bastidas et al. 2013 ).
In the recent years, it has been demonstrated that C. trachomatis can generate a persistent form during its developmental cycle as a consequence of several stress-inducing factors (Di Pietro M et al. 2013; Wyrick 2010) . As a result, normal RBs transform into enlarged and morphologically aberrant RBs, thus stopping the production of infectious EBs (Hogan et al. 2004; Wyrick 2010 ). In particular, C. trachomatis enters into the persistence state in the presence of iron-chelating drugs, which inhibit the developmental cycle and, hence, show its dependence on iron for the achievement of infectious cycle (Raulston 1997; Thompson and Carabeo 2011) . In this regard, iron limitation in D r a f t 4 host cells has been shown to be of the utmost importance for the growth and survival of Chlamydia spp. (Raulston 1997; Al-Younes et al. 2001 ).
Following C. trachomatis infection, cervical epithelial cells produce several pro-inflammatory cytokines including TNF-α, IL-1α, IL-6 and IL-8 that augment the cell inflammatory response thus inducing direct damage to genital tissues. Furthermore, IL-8, in turn, recruits innate immune cells, which are abundant in the genital mucosa and are able to further worsen chronic inflammation and tissue-damage of the reproductive system (Redgrove and McLaughlin 2014) .
Interestingly, IL-8 recruits, duringthe infection/inflammation, neutrophils that synthesize and secrete granules containing lactoferrin (Lf) (Masson et al. 1969 ).
Recently, a great interest in Lf, considered as a prominent component of the first line defense of the host against infections and inflammation, has been raised.
Lf, an 80 kDa iron-binding glycoprotein, is found in most body fluids including vaginal fluid (Valore et al. 2002) . Lf possesses several biological functions dependent and independent from its iron binding ability (Valenti and Antonini 2005) . Among the biological properties related to its iron-withholding ability, Lf inhibits bacterial infections, whereas, independently from iron chelation, its high positive charge favors the binding to microorganisms and/or host cells, thus hindering the adhesion and entry into epithelial cells (Valenti and Antonini 2005) . In addition to these activities, Lf exerts a potent anti-inflammatory activity, protecting infected host cells from damages associated to pathological inflammation. In particular, Lf, independently from its iron binding ability, decreases the synthesis of pro-inflammatory cytokines in infected epithelial cells (Berlutti et al. 2006; Valenti et al. 2011; Puddu et al. 2011; Frioni et al. 2014) .
Given the impact of asymptomatic chlamydial infection on disease outcomes and the multifunctional features of Lf, the aim of our study was to evaluate the effects of bovine milkderivative Lf (bLf) on C. trachomatis infection and on the associated inflammatory state in vitro and in vivo.
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Materials and Methods
Chlamydia trachomatis strain and cell culture C. trachomatis L2 strain 434/Bu (ATCC VR-902B) was obtained from American Type Culture Collection.
The human epithelial HeLa-229 cell line from cervix adenocarcinoma (ATCC ® CCL-2.1™) was cultured at 37°C in Dulbecco's Modified Eagle Medium (D-MEM, Euroclone, Milan, Italy), supplemented with 10% fetal calf serum (FCS, Euroclone, Milan, Italy) , in humidified atmosphere with 5% CO 2 .
Propagation and titration of Chlamydia trachomatis
Elementary body (EB) aliquots of C. trachomatis L2 were stored at −80°C and propagated in HeLa-229 cells, grown in D-MEM supplemented with 10% FCS, as previously described by Mastromarino et al. (2014) . The infectious titer was assessed by immunofluorescence assay (IFA). 
ii) Pre-incubation of bLf with HeLa-229 cells before the infection with C. trachomatis EBs
HeLa-229 cells were pre-incubated in fresh medium in the absence or presence of bLf (100 µg/ml).
After 1h or 3hs of incubation at 37°C in 5% CO 2 , bLf was removed by washing the cell monolayers three times with PBS. Subsequently, HeLa-229 cells were infected with C. trachomatis ata MOI of 0.05 as above described. After 48 h.p.i. at 37°C in 5% CO 2 , the total number of C. trachomatis IFU was determined by IFA.
iii) bLf addition to HeLa-229 cells at the moment of infection with C. trachomatis EBs
In this set of experiments, bLf was added to HeLa-229 cells at the moment of infection. Briefly, HeLa-229 cells were infected with C. trachomatis at a MOI of 0.05 in the absence or presence of bLf (100 µg/ml). After 1 h at 37°C in 5% CO 2 , the cells were washed with PBS to remove the non-
internalized C. trachomatis EBs and fresh medium was added. After 48 h.p.i at 37°C and 5% CO 2 , the total number of C. trachomatis IFU was determined by IFA.
iv) bLf addition to HeLa-229 cells three hours post C. trachomatis infection
HeLa-229 cells were infected with C. trachomatis at a MOI of 0.05. After 1h of incubation at 37°C in 5% CO 2 , the cells were washed with PBS to remove the non-internalized C. trachomatis EBs and fresh medium was added. After further 3hs of incubation at 37°C in 5% CO 2 , fresh medium, with or without bLf (100 µg/ml), was added to the infected cells. After 48 h.p.i. at 37°C and 5% CO 2 , the total number of C. trachomatis IFU was determined by IFA.
Detection of cytokines
Preliminary experiments, carried out with C. trachomatis EBs at a MOI of 0.05, showed a very low cytokine expression by infected HeLa-229 cells. Therefore, HeLa-229 cells were infected with C.
trachomatis EBs at a MOI of 5 in order to reach an higher expression of IL-6 and IL-8 than that observed at the MOI of 0.05. After 1h of incubation, the cells were washed with PBS to remove the non-internalized C. trachomatis EBs and supplemented with fresh medium. After further 3hs of incubation at 37°C in 5% CO 2 , fresh medium, with or without bLf (100 µg/ml), was added to the infected cells. The cytokine production was determined in cell monolayer supernatants by ELISA using Human ELISA Max Deluxe Set (BioLegend, San Diego, CA) after 48 hs of incubation at 37°C in 5% CO 2 .
Study design
We conducted an open-label cohort study in accordance with the ethical principles of the The exclusion of pregnant women during the clinical trial was also considered on the basis of voluntary declaration, lack of treatment effectiveness, side effects, protocol infringement, and missed programmed visits. As a matter of fact, the enrolled pregnant women had a monthly scheduled visit.
Laboratory tests
At each scheduled visit, in addition to standard assays (haematocrit, glycemia, uricemia, bilirubin, glutamicoxaloacetic transaminase, glutamic pyruvic transaminase, cholesterol, triglyceride acid and electrolytes), cervical specimens were collected with polyethylene terephthalate (Dacron) swabs to detect the presence of C. trachomatis.. In addition, cervical fluids were analyzed to detect IL-6
concentrations.
Chlamydia trachomatis detection
Cervical specimens were analyzed by direct immunofluorescence assay (DFA) using Syva
Microtrack kit (Syva Microtrack, Trinity Biotech, USA) according to the manufacturer's instructions. Briefly, the smears were fixed with methanol and stained with fluorescein isothiocyanate conjugated (FITC) monoclonal antibody against C. trachomatis major outer membrane protein (MOMP) for 30 minutes at 37°C in a humid chamber. The slides were examined for the presence of IFUs using fluorescence microscope (100 × magnification).
Treatment against Chlamydia trachomatis infection in pregnant women
Among one hundred ninety-eight pregnant women, seven women, asymptomatically affected by C.
trachomatis, were immediately treated with bLf intravaginal administration. The intravaginal tablet, containing 100 mg of lyophilized bLf 20% iron saturated, was administered every 8 h for 30 days.
The tablets were administered through a vaginal applicator to obtain a fast and adequate dissolution.
If the treatment with bLf intra-vaginal administration for 30 days was ineffective, the pregnant women were submitted to antibiotic therapy (Workowski and Bolan 2015) .
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Maternal side effects
The side effects of bLf intravaginal administration were assessed by monitoring vaginal irritation, itching and burning.
Fetal and newborn side effects
Fetal vital sign assessments were monitored by ultrasonographic measurements of intrauterine growth and through the amount of amniotic fluid, expressed as the amniotic fluid index (AFI).
Newborn weight and Apgar score were registered. Apgar score is a practical method of evaluating the physical condition of a newborn shortly after delivery (Apgar 1953 ). An Apgar score of 0-3 at 5-10 min of age is predictive of high morbidity and mortality, while an Apgar score of 9-10 means the infant is in the best possible conditions.
Statistical analysis
All values were expressed as mean ± standard deviation (SD) of three replicates from three independent in vitro experiments. The concentrations of IL-6 in cervical fluid of pregnant women were expressed as mean values ± SD. Comparison of means was performed by using a two-tailed ttest for independent samples. A value of P < 0.05 was considered statistically significant.
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Results
Effects of bovine lactoferrin on Chlamydia trachomatis infection
We evaluated the effects of bLf, at non-cytotoxic concentration corresponding to 100 µg/ml, on C.
trachomatis infections.
As shown in Figure 1A , no significant reduction in the number of chlamydial IFUs was observed when chlamydial EBs were pre-incubated with bLf for 1h or 3hs, indicating no direct effect of bLf on C. trachomatis.
In contrast, bLf was able to inhibit C. trachomatis entry into host cells as evidenced by a significant reduction of chlamydial IFU observed when HeLa-229 monolayers were pre-incubated with bLf for 1h or 3hs (1h pre-incubation: p=0.0008; 3hs pre-incubation: p=0.00007) (Figure 1 B, C) . The inhibitory effect of bLf on C. trachomatis entry was more pronounced when HeLa-229 cells were pre-incubated with bLf for 3hs as compared to 1h (p=0.0124) ( Figure 1C ).
To further confirm the inhibitory effect of bLf on C. trachomatis entry into host cells, bLf was added at the moment of HeLa-229 monolayer infection with C. trachomatis. The presence of bLf during the infection phase significantly inhibited C. trachomatis entry into HeLa-229 cells at the same extent evidenced when bLf was pre-incubated with cell monolayers for 1h or 3hs (Figure 1 B, C, D). In order to determine whether bLf was also able to inhibit chlamydial replication into host cell, bLf was added after 3hs of C. trachomatis infection. The addition of bLf under these experimental conditions resulted in no significant reduction of the number of intracellular chlamydial IFUs (p=0.28) (Figure 1 E) .
Effect of lactoferrin on IL-6 and IL-8 cytokine production by Chlamydia trachomatis-infected
HeLa-229 cells
To investigate the effect of bLf on the inflammatory response, HeLa-229 cells were infected with C.
trachomatis at a MOI of 5 and, after 3hs of infection, bLf was added to the medium. Of note, the addition of bLf after 3hs post infection did not influence the intracellular number of C. trachomatis trachomatis induced a significant increase of both IL-6 and IL-8 levels. The addition of bLf to infected cells 3hs post infection determined a significant decrease of both IL-6 and IL-8 levels as compared to bLf-untreated infected cells (P<0.05). In particular, bLf significantly decreased IL-6
and IL-8 concentrations, even if cytokine levels remained higher than those synthesized by noninfected cell monolayers.
Clinical trial
Among one hundred ninety-eight pregnant women, 16 women, affected by bacterial vaginosis unrelated to C. trachomatis, and 6 women, for protocol violation, were excluded. One hundred seventy-six pregnant women completed the study and, among them, seven asymptomatic pregnant women, positive to C. trachomatis DFA and showing high concentration of IL-6 in cervical fluids, were treated with the intravaginal administration of bLf (100 mg) every 8hs for 30 days.
After one month, six out of seven cervical specimens were negative to C. trachomatis DFA and the cervical fluids showed a decrease in IL-6 concentration (from mean values of 250±19 to 50±11 pg/ml). One out of seven pregnant women was positive to C. trachomatis DFA and cervical IL-6 levels did not decrease, ranging between about 270 and 300 pg/ml (Table 1) C. trachomatis is an obligate, intracellular pathogen responsible for the most common bacterial sexually transmitted disease worldwide, causing acute and chronic infections. Differently from the acute infection, cured with oral or topical administration of antibiotics, the chronic one is difficult to eradicate and needs prolonged therapies, thus increasing the risk of developing antibiotic resistance (Kohlhoff and Hammerschlag 2015) .
Therefore, novel alternative therapies are needed (Sessa et al. 2015) . The difficulty to find new agents anti-C. trachomatis infection resides in the complex life-cycle of this peculiar pathogen. In fact, C. trachomatis has a unique biphasic developmental cycle alternating between the extracellular infectious EBs metabolically inactive and the intracellular non-infectious RBs, metabolically active.
Of note, intracellular bacterial pathogens require intracellular nutrients, including iron, for replication in mammalian cells, and chlamydiae are no exception (Raulston 1997) .
Concerning the first phase of C. trachomatis infection, classical anti-bacterial drugs are ineffective because EBs are metabolically inactive.
Conversely, anti-bacterial drugs could be active against intracellular replicative RBs, since they are metabolically active. However, antibacterial drugs cannot usually enter inside host cells.
A further key issue is represented by the intracellular re-differentiationof RBs (after intracellular replication) into EBs, which are released following the lysis of host cells, ready to infect neighboring epithelial cells and, hence, perpetuate the infectious process (Belland et al. 2003) .
Therefore, an ideal drug against C. trachomatis infection should: Lf is thought to play a pivotal role in the prevention of infections. Its ability to sequester iron from potential pathogens is considered as an important feature in order to contrast infections. Moreover, its cationic charge is responsible for the binding to bacterial and cell surface components (Valenti and Antonini 2005) . This Lf property has been shown to inhibit the adhesion and entry into epithelial cells of several facultative intracellular bacteria (Longhi et al. 1993; Ajello et al. 2002; Di Biase et al. 2004; Willer et al. 2004; Berlutti et al. 2008) ; however Lf activity against obligate intracellular bacteria as C. trachomatis has never been observed.
In this study, we utilized a preparation of bLf, iron saturated at 20%, to consent further iron chelation, an essential nutrient for C. trachomatis developmental cycle (Raulston 1997) . In facts, in the absence of free, available iron, C. trachomatis enters into a persistent state, as evidenced by the addition of iron-chelating agents, such as deferoxamine mesylate (DFO) or 2,2′-bipyridyl (Bpdl), to C. trachomatis infected cell monolayers, leading to small-sized inclusions containing enlarged, aberrant and non-dividing RBs (Thompson and Carabeo 2011) , unable to generate infectious progeny (Wyrick 2010) .
Differently from data reported by Thompson and Carabeo (2011) , we found that the addition of bLf to HeLa cell monolayers 3hs post-infection resulted in no significant reduction of the number of intracellular chlamydial IFU (p=0.28) (Figure 1 E) and of infectious progeny.These conflicting data could be due to the higher effective concentrations of iron-chelating agents (from 100 to 200 µM) (Thompson and Carabeo 2011) as compared to 1.25 µM bLf, corresponding to 2.5 µM iron binding sites, used in this study.
We believe to be very interesting that bLf does not affect both the replication of RBs and the induction of aberrant RBs, thus avoiding the "silent" reservoir that leads to chronic infection and inflammation.
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In fact, aberrant RBs can contribute to chronic inflammation, even if this aspect is still under debate. Of note, the recurrent chlamydial disease may also result from the persistence of the microorganism after unresolved infections (Wyrick 2010) .
At the best of our knowledge, we demonstrated, for the first time, that the incubation of cell monolayers with bLf before the infection or at the moment of the infection inhibited, in a significant part, C. trachomatis adhesion and entry into epithelial cells. Therefore, the inhibition of C.
trachomatis infectivity by bLf was dependent on its interaction with cell surface. As a matter of fact, bLf was able to bind to cell surface glycosaminoglycans as well as to heparan sulfate proteoglycans (Wu et al. 1995; Lang et al. 2011) , potential receptors for C. trachomatis adhesion (Stallmann and Hegemann 2015) .
Conversely, the pre-incubation of bLf with C. trachomatis did not influence its infectivity, supporting that the specific interaction between bLf and epithelial host cells seems to be the sole pivotal mechanism responsible for the inhibition of C. trachomatis invasion.
Similarly to the results obtained in epithelial cell monolayers infected with other facultative intracellular pathogens (Berlutti et al. 2006; Valenti et al. 2011; Frioni et al. 2014) , the addition of bLf significantly decreased the IL-8 and IL-6 levels synthetized by C. trachomatis infected cells. To avoid that the IL-8 and IL-6 decrease was related to the different number of C. trachomatis IFUs, these experiments were carried out adding bLf 3 hs post infection. These results demonstrated once again the ability of bLf to down-regulate pro-inflammatory cytokine synthesis. Although it has been known for years that exogenous Lf localized to cell nucleus (Ashida et al. 2004; Suzuki et al. 2008; Valenti et al. 2011) , the mechanisms by which bLf could perform its anti-inflammatory activity are still under debate. 
